Overview

Principal Investigator

Massimo Gadina, Ph.D.

Dr. Massimo Gadina, director of the Office of Science and Technology, is exploring immune-mediated diseases with a particular emphasis on the biology of cytokines and their relative signaling pathways.

The development of accurate and reproducible immune monitoring assays is essential to determine the immune responses in patients receiving novel immune therapies and ultimately transitioning these therapies from the clinical trial phase to standard of care. The goal of the Translational Immunology Section (TIS) is to develop cutting edge immune monitoring technology that will be made available to all NIAMS investigators.

Services

The Translational Immunology Section provides NIAMS scientists with:

  • Services, consultative advice and in-depth instructions in a variety of immunologic methods to facilitate their interpretation of immunoassays most relevant to a particular clinical trial or to study a particular patient.
  • State-of-the-art immunoassays such as multicolor flow cytometry and Luminex, enabling NIAMS clinicians to monitor the immune responses of their clinical trial patients.
  • Analysis of a reference population to define baseline responses, ensuring quality control checks that will validate the reproducibility of these results.

Staff

Director
Chief
301-443-5457
Postbaccalaureate Trainee
301-435-0789
Contractor
301-451-2615
Postbaccalaureate Trainee
301-480-4254
Biologist
301-402-1917
Research Assistant
301-496-5200
Research Fellow
301-402-5571

Image & Media Gallery

Scientific Publications

Zhou Q, Yang D, Ombrello AK, Zavialov AV, Toro C, Zavialov AV, Stone DL, Chae JJ, Rosenzweig SD, Bishop K, Barron KS, Kuehn HS, Hoffmann P, Negro A, Tsai WL, Cowen EW, Pei W, Milner JD, Silvin C, Heller T, Chin DT, Patronas NJ, Barber JS, Lee CC, Wood GM, Ling A, Kelly SJ, Kleiner DE, Mullikin JC, Ganson NJ, Kong HH, Hambleton S, Candotti F, Quezado MM, Calvo KR, Alao H, Barham BK, Jones A, Meschia JF, Worrall BB, Kasner SE, Rich SS, Goldbach-Mansky R, Abinun M, Chalom E, Gotte AC, Punaro M, Pascual V, Verbsky JW, Torgerson TR, Singer NG, Gershon TR, Ozen S, Karadag O, Fleisher TA, Remmers EF, Burgess SM, Moir SL, Gadina M, Sood R, Hershfield MS, Boehm M, Kastner DL, Aksentijevich I. Early-onset stroke and vasculopathy associated with mutations in ADA2. N Engl J Med. 2014 Mar 6;370(10):911-20. doi: 10.1056/NEJMoa1307361. Epub 2014 Feb 19.

Furumoto Y, Gadina M. The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders. BioDrugs. 2013 Jun 7. [Epub ahead of print]

Kontzias A, Laurence A, Gadina M, O'Shea JJ. Kinase inhibitors in the treatment of immune-mediated disease. F1000 Med Rep. 2012;4:5. Epub 2012 Mar 1.

HiJAKing Innate Lymphoid Cells?  Sciumè G, Le MT, Gadina M.Front Immunol. 2017 Apr 13;8:438. doi: 10.3389/fimmu.2017.00438. eCollection 2017. No abstract available. PMID: 28450869

Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Furumoto Y, Smith CK, Blanco L, Zhao W, Brooks SR, Thacker SG, Abdalrahman Z, Sciumè G, Tsai WL, Trier AM, Nunez L, Mast L, Hoffmann V, Remaley AT, O'Shea JJ, Kaplan MJ, Gadina M. Arthritis Rheumatol. 2017 Jan;69(1):148-160. doi: 10.1002/art.39818. PMID: 27429362

Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behçet's disease susceptibility.  Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, Le J, Blake M, Erer B, Kawagoe T, Ustek D, Tugal-Tutkun I, Seyahi E, Ozyazgan Y, Sousa I, Davatchi F, Francisco V, Shahram F, Abdollahi BS, Nadji A, Shafiee NM, Ghaderibarmi F, Ohno S, Ueda A, Ishigatsubo Y, Gadina M, Oliveira SA, Gül A, Kastner DL, Remmers EF. Nat Genet. 2017 Mar;49(3):438-443. doi: 10.1038/ng.3786. Epub 2017 Feb 6. PMID: 28166214

Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors.  Layh-Schmitt G, Lu S, Navid F, Brooks SR, Lazowick E, Davis KM, Montagna C, Gadina M, Colbert RA.  Clin Rheumatol. 2017 Jan;36(1):143-154. doi: 10.1007/s10067-016-3469-5. Epub 2016 Nov 18.  PMID:  27864696

Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease.  Zhou Q, Yu X, Demirkaya E, Deuitch N, Stone D, Tsai WL, Kuehn HS, Wang H, Yang D, Park YH, Ombrello AK, Blake M, Romeo T, Remmers EF, Chae JJ, Mullikin JC, Güzel F, Milner JD, Boehm M, Rosenzweig SD, Gadina M, Welch SB, Özen S, Topaloglu R, Abinun M, Kastner DL, Aksentijevich I.  Proc Natl Acad Sci U S A. 2016 Sep 6;113(36):10127-32. doi: 10.1073/pnas.1612594113. Epub 2016 Aug 24. PMID: 27559085

Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease.  Zhou Q, Wang H, Schwartz DM, Stoffels M, Park YH, Zhang Y, Yang D, Demirkaya E, Takeuchi M, Tsai WL, Lyons JJ, Yu X, Ouyang C, Chen C, Chin DT, Zaal K, Chandrasekharappa SC, P Hanson E, Yu Z, Mullikin JC, Hasni SA, Wertz IE, Ombrello AK, Stone DL, Hoffmann P, Jones A, Barham BK, Leavis HL, van Royen-Kerkof A, Sibley C, Batu ED, Gül A, Siegel RM, Boehm M, Milner JD, Ozen S, Gadina M, Chae J, Laxer RM, Kastner DL, Aksentijevich I.  Nat Genet. 2016 Jan;48(1):67-73. doi: 10.1038/ng.3459. Epub 2015 Dec 7.  PMID: 26642243

Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Schwartz DM, Bonelli M, Gadina M, O'Shea JJ. Nat Rev Rheumatol. 2016 Jan;12(1):25-36. doi: 10.1038/nrrheum.2015.167. Epub 2015 Dec 3. Review. PMID: 26633291

Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Brehm A, Liu Y, Sheikh A, Marrero B, Omoyinmi E, Zhou Q, Montealegre G, Biancotto A, Reinhardt A, de Jesus AA, Pelletier M, Tsai WL, Remmers EF, Kardava L, Hill S, Kim H, Lachmann HJ, Megarbane A, Chae JJ, Brady J, Castillo RD, Brown D, Casano AV, Gao L, Chapelle D, Huang Y, Stone D, Chen Y, Sotzny F, Lee CC, Kastner DL, Torrelo A, Zlotogorski A, Moir S, Gadina M, McCoy P, Wesley R, Rother KI, Hildebrand PW, Brogan P, Krüger E, Aksentijevich I, Goldbach-Mansky R. J Clin Invest. 2016 Feb;126(2):795. doi: 10.1172/JCI86020. Epub 2016 Feb 1. No abstract available.  PMID: 26829627

Latest News

Research Brief | January 9, 2017

Tofacitinib Shows Potential for Treating Lupus

A drug that effectively treats rheumatoid arthritis (RA) and can improve symptoms in other autoimmune diseases may also control the symptoms associated with systemic lupus erythematosus (SLE or lupus) and potentially slow the disease’s progression.

Contact Us

Ronnie Gladney

Contractor
10 Center Drive
BG 10 RM 6N204
Bethesda MD 20814
Last Reviewed: 02/25/2017